Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
DOMA Perpetual filed a preliminary proxy statement seeking to elect three director nominees to Pacira BioSciences' board and to replace management ahead of the June 9, 2026 annual meeting. The filing says DOMA and affiliates beneficially own up to 2,777,794 shares and argues the board mismanaged EXPAREL litigation and capital allocation.
DOMA contends EXPAREL represents ~80% of Pacira revenue, cites a prior court loss and settlement that it says ceded roughly 38% of future EXPAREL volumes, and proposes removal of the CEO, formation of a sales-focused subcommittee, and shareholder approval of any sale.
Pacira BioSciences reported that Vanguard Portfolio Management beneficially owned 2,585,964 shares of common stock, representing 6.38% of the class as of 03/31/2026. The filing discloses sole voting power of 84,678 shares and sole dispositive power over 2,585,964 shares. The Schedule 13G states these holdings reflect securities managed by Vanguard Portfolio Management LLC and affiliated investment divisions and was signed on 05/01/2026.
Vanguard Capital Management reported beneficial ownership of 2,088,291 shares of Pacira BioSciences Inc common stock, representing 5.15% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 2,088,291 shares and sole voting power over 304,242 shares.
The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities and is signed by a representative on 05/01/2026.
Pacira BioSciences, Inc. reported net product sales of $177.4M for the quarter ended March 31, 2026, up from $167.6M a year earlier, driven mainly by EXPAREL and ZILRETTA. Net income was $2.9M, down from $4.8M, as higher operating expenses and lower other income offset revenue growth.
EXPAREL generated $143.3M in sales, ZILRETTA $26.8M, iovera° $6.2M and veterinary bupivacaine liposome injectable suspension $1.2M. Operating cash flow was $25.7M, with cash and cash equivalents of $144.3M and total debt of $367.7M, including $281.7M of 2.125% convertible notes due 2029.
The company repurchased 2.24 million shares for $50.4M under its $300M authorization, leaving $100M available, and ended the period with 39.35 million common shares outstanding. Pacira continues to focus on its non-opioid pain portfolio, led by EXPAREL, ZILRETTA, and iovera°, while advancing pipeline programs such as gene therapy candidate PCRX-201.
Pacira BioSciences reported first quarter 2026 revenue of $177.4 million, up 5% from $168.9 million a year earlier, driven by growth across its non‑opioid pain portfolio. EXPAREL sales were $143.3 million, up 5%, ZILRETTA reached $26.8 million, up 15%, and iovera° rose 21% to $6.2 million.
GAAP net income was $2.9 million, or $0.07 per share, down from $4.8 million, or $0.10 per share, reflecting higher R&D and SG&A spending. Non‑GAAP net income was $24.5 million, or $0.60 per share, versus $30.0 million a year ago, and adjusted EBITDA was $40.2 million, compared with $44.1 million.
The company ended the quarter with $202.2 million in cash, cash equivalents and available‑for‑sale investments, and repurchased 2.2 million shares for $50.0 million, leaving 39.3 million shares outstanding at March 31, 2026. Pacira completed enrollment in its Phase 3 ZILRETTA shoulder osteoarthritis study and highlighted ongoing development of gene therapy candidate PCRX‑201. Full‑year 2026 guidance was reiterated, including EXPAREL sales of $600–$620 million and total revenue of $745–$770 million, with targeted non‑GAAP gross margin of 77–79%.
Pacira BioSciences Chief Financial Officer Shawn Cross reported option-related transactions in company common stock. On April 23, 2026, he exercised stock options to acquire 12,941 shares at $16.45 per share and sold 12,941 shares in open-market trades at a weighted average price of $25.16, within a range of $25.00 to $25.41. The filing shows these moves were made under a pre-established Rule 10b5-1 trading plan. After the transactions, he directly owned 105,341 shares of Pacira common stock.
PCRX affiliate submitted a Form 144 reporting proposed resale of Common Stock and related recent transactions. The filing lists Common stock tied to an options grant dated 11/04/2024 and includes sales by Shawn Cross: 7,714 shares for $193,912.22 on 04/20/2026, 2,845 shares for $71,149.18 on 04/21/2026, and 1,500 shares for $37,520.55 on 04/22/2026. The filing date shown is 04/23/2026.
Pacira BioSciences Chief Financial Officer Shawn Cross exercised stock options and sold shares in a pre-planned set of trades. Over April 20–22, he exercised options for 12,059 shares of common stock at an exercise price of $16.45 per share and sold the same number of shares in open-market transactions at weighted average prices around $25.01–$25.14 per share.
After these transactions, he directly holds 105,341 shares of Pacira common stock. The filing states that the option exercises and sales were carried out under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic.